Press releases

PanTera signs an agreement with SK Biopharmaceuticals for the supply of actinium-225On February 25, 2025, SK Biopharmaceuticals announced their collaboration with PanTera marking a significant step forward in the global interest surrounding Actinium-225. This partnership leverages PanTera's expertise in delivering high-purity Actinium-225, a crucial resource for innovative therapeutic applications for cancer treatments.26/02/2025Read more
27/01/2025
A new Partnership with Cody ASThis partnership is a significant milestone for our radiochemistry process. Cody’s expertise in engineering complex radiochemical systems gives us confidence that they will deliver innovative and reliable solutions to meet the growing global demand for Ac-225!Read more
11/09/2024
PanTera secures EUR 93 million in oversubscribed Series A round to accelerate global actinium-225 productionPanTera today announces that it has completed a EUR 93 million oversubscribed Series A fundraise led by EQT Life Sciences, with additional equity and debt funding bringing the total amount raised to EUR 134 million. Sven Van den Berghe, CEO of PanTera, said: “With this funding, we are now en route to realise our vision of providing a “Better Fight for Life” to cancer patients worldwide by becoming a dependable global 225Ac supplier.” Read More to see our full Press Release.Read more
Radioisotope production facility with Tractebel, MODULO and PanTera
28/03/2024
Tractebel and Modulo architects strengthen their partnership with PanTera to design a medical radioisotope production facilityJointly with its partner Modulo architects, Tractebel will combine its infrastructure and nuclear expertise to support the design and construction of PanTera's actinium-225 production facility in Belgium, enabling breakthrough cancer treatment production Read more
PanTera signs a second agreement for the supply of actinium-225PanTera’s continues to deploy its strategy to become a market leader into the production and distribution of Ac22514/03/2024Read more
PanTera signs agreement with Bayer for the supply of actinium-225Agreement demonstrates PanTera’s unique ability to support the radionuclide therapeutics industry in bringing new cancer treatments to patients.13/02/2024Read more
PanTera and TerraPower Isotopes join forces to accelerate access to actinium-225Strategic collaboration signed to support the development of radiopharmaceuticals in the fight against cancer26/06/2023Read more
IBA and SCK CEN launch Pantera, a joint-venture to produce actinium-225IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, and the Belgian Nuclear Research Centre SCK CEN today announced the name of their joint-venture: Pantera SA/NV22/09/2022Read more